Terray Therapeutics Unveils TerraBind AI Model: 20% More Accurate and 26x Faster Than Boltz-2 in Protein Binding Prediction

on

Terray Therapeutics announced EMMI Predict:
TerraBind, a new AI model for predicting small molecule potency that achieves 20% higher accuracy than the open-source Boltz-2 model across 18 internal drug discovery targets and 16% higher Pearson correlation on the CASP16 benchmark12.

TerraBind runs 26x faster than Boltz-2, reducing inference costs by 96% by using coarse-grained structural representations instead of computationally intensive all-atom diffusion processes124.

The model is part of Terray's EMMI platform, powered by a 14 billion unique target-molecule measurement dataset, accelerating de-novo small molecule drug discovery for partners like BMS, Gilead, and Odyssey Therapeutics12.

TerraBind supports evaluating millions of molecules, enabling better candidate selection and faster optimization in drug development, with Terray expecting its first clinical candidate in 202712.

Sources:

1. https://www.businesswire.com/news/home/20260212470275/en/Terrays-New-EMMI-Predict-Model-Sets-an-Industry-Performance-Standard-Delivering-Best-In-Class-Accuracy-26x-Faster

2. https://www.genengnews.com/topics/artificial-intelligence/terrays-ai-model-accelerates-drug-potency-prediction-pose-not-needed/

4. https://www.drugdiscoverytrends.com/terray-says-terrabind-delivers-26x-faster-inference-than-boltz-2-by-skipping-diffusion-based-coordinate-generation/